OBJECTIVE: To describe the prevalence, distribution and degree of control of type 2 diabetes (T2D) in Mexican population. MATERIAL AND METHODS: Subjects were classified as previously diagnosed T2D (PD); or as "finding of the survey" (FS) (glucose >or=126 mg/dL). Hemoglobin A1c was measured in PD-subjects. RESULTS: The prevalence for PD-T2D was 7.34% (95%CI 6.3, 8.5) and for FS 7.07% (95%CI 6.1, 8.1), summing 14.42%; (7.3 million diabetics). 5.3% of PD-T2D were in good, 38.4% in poor and 56.2% very poor control. Older age (OR=0.96, 95%CI 0.94, 0.97), lower BMI (OR=0.95, 95%CI 0.91, 1.0), were protective for poor control. Affiliation to private services (OR=1.77, 95%CI 0.98, 3.13), larger T2D duration (OR=1.05, 95%CI 1.01, 1.08), and combining oral medication and insulin (OR=16.1, 95%CI 1.61, 161) were riskier. CONCLUSIONS: We found an alarming prevalence of T2D in Mexican population; the majority of PD diabetics are in poor control. Research on the latter is warranted.
OBJECTIVE: To describe the prevalence, distribution and degree of control of type 2 diabetes (T2D) in Mexican population. MATERIAL AND METHODS: Subjects were classified as previously diagnosed T2D (PD); or as "finding of the survey" (FS) (glucose >or=126 mg/dL). Hemoglobin A1c was measured in PD-subjects. RESULTS: The prevalence for PD-T2D was 7.34% (95%CI 6.3, 8.5) and for FS 7.07% (95%CI 6.1, 8.1), summing 14.42%; (7.3 million diabetics). 5.3% of PD-T2D were in good, 38.4% in poor and 56.2% very poor control. Older age (OR=0.96, 95%CI 0.94, 0.97), lower BMI (OR=0.95, 95%CI 0.91, 1.0), were protective for poor control. Affiliation to private services (OR=1.77, 95%CI 0.98, 3.13), larger T2D duration (OR=1.05, 95%CI 1.01, 1.08), and combining oral medication and insulin (OR=16.1, 95%CI 1.61, 161) were riskier. CONCLUSIONS: We found an alarming prevalence of T2D in Mexican population; the majority of PD diabetics are in poor control. Research on the latter is warranted.
Authors: Victor Rusu; Eitan Hoch; Josep M Mercader; Danielle E Tenen; Melissa Gymrek; Christina R Hartigan; Michael DeRan; Marcin von Grotthuss; Pierre Fontanillas; Alexandra Spooner; Gaelen Guzman; Amy A Deik; Kerry A Pierce; Courtney Dennis; Clary B Clish; Steven A Carr; Bridget K Wagner; Monica Schenone; Maggie C Y Ng; Brian H Chen; Federico Centeno-Cruz; Carlos Zerrweck; Lorena Orozco; David M Altshuler; Stuart L Schreiber; Jose C Florez; Suzanne B R Jacobs; Eric S Lander Journal: Cell Date: 2017-06-29 Impact factor: 41.582
Authors: Manuel González-Ortiz; Esperanza Martínez-Abundis; José A Robles-Cervantes; Maria G Ramos-Zavala; Carmelita Barrera-Durán; Jorge González-Canudas Journal: Diabetes Technol Ther Date: 2012-09-13 Impact factor: 6.118
Authors: Amy L Williams; Suzanne B R Jacobs; Hortensia Moreno-Macías; Alicia Huerta-Chagoya; Claire Churchhouse; Carla Márquez-Luna; Humberto García-Ortíz; María José Gómez-Vázquez; Noël P Burtt; Carlos A Aguilar-Salinas; Clicerio González-Villalpando; Jose C Florez; Lorena Orozco; Christopher A Haiman; Teresa Tusié-Luna; David Altshuler Journal: Nature Date: 2013-12-25 Impact factor: 49.962
Authors: Aimee Afable-Munsuz; Elizabeth Rose Mayeda; Eliseo J Pérez-Stable; Mary N Haan Journal: Am J Public Health Date: 2013-03-14 Impact factor: 9.308